Recently, the Chamber of Deputies approved the Amendment no. 48 to Public Health Insurance Law. The new legislation, valid as of 1st January 2022, addresses the topic of "orphan drugs" and HTA processes, which are usually highly relevant for patients with rare diseases such as HAE. This new bill sets special conditions for reimbursement as part of the national public health insurance system and it enables the involvement of patient organizations in the approval process.
HAE Junior patient organization closely monitors these legislative changes and regularly provides updates for the patient community (and not only) via HAE Junior Newsletter.